Morning Versus Bedtime Dosing of Antihypertensive Medication

Prior treatment

• Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;
• Concomitant diseases that need taking medications influencing BP;
• Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.

Other illness

• Secondary hypertension;
• Coronary heart disease, myocardial infarction or stroke within recent 6 months;
• Atrial fibrillation or frequent arrhythmia;

Lab values

• Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol/L; and plasma potassium ≥5.5 mmol/L or ≤3.5mmol/L;
• Contraindications of angiotensin II receptor blocker or calcium channel blocker;

Other

• Need to work at night;
• Ambulatory BP monitoring was invalid (\<70% valid readings, or \<20 daytime readings or \<7 nighttime readings);
• Pregnant or lactating women;

• Male or female patients aged 18-70 years old;
• Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;
• In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP \< 100 mmHg;
• The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg;
• The average of bilateral brachial-ankle pulse wave velocity ≥14m/s;
• Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.